Agenda

- Approval of 2013 General Assembly Minutes
- SIOG 2012-2014 Progress Report
- 2013, 2014 Financial Status & 2015 Budget Projection
- Constitution Amendment – Article 8
- Introduction to SIOG President 2014-2016: Dr. Etienne Brain
Approval of the Minutes of the 2013 General Assembly

VOTE
Key Accomplishments

➢ Research and Science
  ➢ Educational content of the annual meeting
    – Established 5 meeting tracks
    – Recruited track leaders with expertise in each area
    – Increased quality of abstracts
    – Refined the abstract review process
    – Increase in oral abstracts
    – Increase number of poster walks
    – Addition of poster reception for the meeting
    – Awards celebrating scientific excellence
Key Accomplishments

Education Through Diverse Modalities

- Increase task force activities
  - Foster our mission of education
  - Leverage the expertise of our membership
  - High quality publications
  - Generate revenue
- Build collaborations with education partners
  - Medscape
  - Plexus Communication
  - European School of Oncology
  - ecancer
Key Accomplishments

Education Through Diverse Modalities

- Collaboration with other societies
  - ASCO
  - EUGMS
  - MASCC
  - IPOS

- Annual scientific meeting
  - SIOG APAC (Singapore, July 2014)

- Fostering the growth of the Journal of Geriatric Oncology
JGO Milestones

- 2010
  - *Journal of Geriatric Oncology* launched as the official journal of SIOG

- 2011
  - Indexed by Science Citation Index Expanded, Current Contents/ Clinical Medicine, and Journal Citation Reports
  - First impact factor awarded by Thomas Reuters
  - 2011 Impact factor: 1.000

- 2012
  - Indexed by PubMed/Medline
  - Launched “Meet the Expert” series
  - 2012 Impact factor: 1.118
  - Expansion of the editorial team
    - 2 deputy editors and 4 new associate editors

- 2013
  - 2013 Impact factor: 1.146
  - Launch of the “Geriatrics for Oncologists” series
  - Increasing to 6 issues a year
Key Accomplishments

- Foster the Activities of Our Leadership Body
  - Working closely with executive committee
  - Increase the engagement of the board
    - Work to develop a strategic plan
    - Foster their activities
  - Expanding the expertise in the board
    - Formation of the Nursing and Allied Health professional group
    - Formation of Young SIOG
  - Succession planning
Supporting Our Members

Members → Advance Geriatric Oncology → Help Patients & Families

Members

SIOG Committees

SIOG Board Members

Central Office:
Laurence Verhagen & Laurence Jocaille

Foundation and Leadership of Current Advisors & Board Members
2013, 2014 Financial Status & 2015 Budget Projection
<table>
<thead>
<tr>
<th></th>
<th>Sept Act YTD 2013</th>
<th>Dec Act YTD 2013</th>
<th>Rev Budget 2013</th>
<th>Variance from Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Ordinary Income/Expense</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Income</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. INCOME</td>
<td>512'687</td>
<td>512'687</td>
<td>460'875</td>
<td>51'812</td>
</tr>
<tr>
<td>Deferred income for 2014 projects</td>
<td>-119'119</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total Income</strong></td>
<td>512'687</td>
<td>393'568</td>
<td>460'875</td>
<td>-67'307</td>
</tr>
<tr>
<td><strong>2. EXPENSES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.1 Salaries and related costs</td>
<td>140'917</td>
<td>199'066</td>
<td>201'210</td>
<td>-2'144</td>
</tr>
<tr>
<td>2.2 Outsourced Services</td>
<td>6'746</td>
<td>9'014</td>
<td>6'300</td>
<td>2'714</td>
</tr>
<tr>
<td>2.3 Travel, projects, meetings &amp; representation</td>
<td>28'788</td>
<td>61'164</td>
<td>115'500</td>
<td>-54'336</td>
</tr>
<tr>
<td>2.4 Communication &amp; marketing</td>
<td>23'470</td>
<td>30'919</td>
<td>27'000</td>
<td>3'919</td>
</tr>
<tr>
<td>2.5 Office accommodation</td>
<td>8'171</td>
<td>10'677</td>
<td>12'960</td>
<td>-2'283</td>
</tr>
<tr>
<td>2.6 Office Costs and reserves</td>
<td>8'795</td>
<td>69'774</td>
<td>67'000</td>
<td>2'774</td>
</tr>
<tr>
<td>2.7 Other Charges</td>
<td>486</td>
<td>545</td>
<td>1500</td>
<td>-955</td>
</tr>
<tr>
<td><strong>Total Expense</strong></td>
<td>217'373</td>
<td>381'159</td>
<td>431'470</td>
<td>-50'311</td>
</tr>
<tr>
<td><strong>Net Ordinary Income</strong></td>
<td>295'314</td>
<td>12'409</td>
<td>29'405</td>
<td>-16'996</td>
</tr>
<tr>
<td><strong>Profit for the Year</strong></td>
<td>295'314*</td>
<td>12'409</td>
<td>29'405</td>
<td>-16'996</td>
</tr>
</tbody>
</table>

*295'314= corresponds to 3 months operating costs (103’786), reserve (60’000), deferred income for 2014 projects (119’119) and profit of the year (12’409).
2014 Financial situation in a nutshell

- SIOG is a growing society: represented by increase of turnover

<table>
<thead>
<tr>
<th></th>
<th>2012</th>
<th>2013</th>
<th>2014</th>
<th>2015</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>153'500 CHF</td>
<td>381'159 CHF</td>
<td>441'140* CHF</td>
<td>643'664 CHF**</td>
</tr>
</tbody>
</table>

*Forecasted end of 2014
**Budgeted for 2015

- SIOG finances are healthy:
  4'536 CHF of accrued expenses = accounts payable
  51'150 CHF of accounts receivable (invoiced during the last month, for 2015)

- SIOG has the necessary cash flow to operate with 401'009 CHF in the bank

- SIOG has defined a reserve fund strategy that will lead us to build a reserve fund corresponding to up to 8 months of fixed operating costs (191’784 CHF value of today) by the end of 2017.

<table>
<thead>
<tr>
<th></th>
<th>Payments</th>
<th>Reserve</th>
</tr>
</thead>
<tbody>
<tr>
<td>2012</td>
<td></td>
<td>0</td>
</tr>
<tr>
<td>2013</td>
<td>60'000</td>
<td>60'000</td>
</tr>
<tr>
<td>2014</td>
<td>40'000</td>
<td>100'000</td>
</tr>
<tr>
<td>2015</td>
<td>40'000</td>
<td>140'000</td>
</tr>
<tr>
<td>2016</td>
<td>25'000</td>
<td>165'000</td>
</tr>
<tr>
<td>2017</td>
<td>25'000</td>
<td>190'000</td>
</tr>
<tr>
<td>2018</td>
<td>25'000</td>
<td>215'000</td>
</tr>
</tbody>
</table>
## Snapshot Financial Situation
**- as of September 30, 2014 -**

<table>
<thead>
<tr>
<th>Ordinary Income/Expense</th>
<th>September Act YTD 2014</th>
<th>Budget 2014</th>
<th>Variance from Budget</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>1. INCOME</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Income</td>
<td>540'165</td>
<td>542'800</td>
<td>-2'635</td>
</tr>
<tr>
<td><strong>2. EXPENSES</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.1 Salaries and related costs</td>
<td>164'409</td>
<td>214'894</td>
<td>-50'485</td>
</tr>
<tr>
<td>2.2 Outsourced Services</td>
<td>6'518</td>
<td>9'184</td>
<td>-2'666</td>
</tr>
<tr>
<td>2.3 Travel, projects, meetings /representation</td>
<td>77'065</td>
<td>233'500</td>
<td>-156'435</td>
</tr>
<tr>
<td>2.4 Communication &amp; marketing</td>
<td>16'421</td>
<td>34'000</td>
<td>-17'579</td>
</tr>
<tr>
<td>2.5 Office accommodation</td>
<td>8'018</td>
<td>11'006</td>
<td>-2'988</td>
</tr>
<tr>
<td>2.6 Office Costs &amp; reserve</td>
<td>10'480</td>
<td>27'276</td>
<td>-16'796</td>
</tr>
<tr>
<td>2.7 Other Charges</td>
<td>326</td>
<td>1'500</td>
<td>-1'174</td>
</tr>
<tr>
<td>Total Expenses</td>
<td>283'237</td>
<td>531'360</td>
<td>-248'123</td>
</tr>
<tr>
<td>Net Ordinary Income</td>
<td>256'928</td>
<td>11'440</td>
<td>245'488</td>
</tr>
<tr>
<td>Net result for the Year*</td>
<td>256'928*</td>
<td>11'440</td>
<td>245'488</td>
</tr>
</tbody>
</table>

* 256'928 CHF corresponds to 3 months operating costs, reserve, deferred income for 2015 projects and profit of the year.
## Financial Situation 2014

<table>
<thead>
<tr>
<th>Ordinary Income/Expense</th>
<th>Dec Act YTD 2013</th>
<th>Budget 2014</th>
<th>Forecast 2014</th>
<th>Variance from Budget from forecast and budget</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Income</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1. INCOME</td>
<td>371'883</td>
<td>542'800</td>
<td>652'152</td>
<td>109'352</td>
</tr>
<tr>
<td>Deferred Income for 2015 projects</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total Income</td>
<td>371'883</td>
<td>542'800</td>
<td>453'152</td>
<td>109'352</td>
</tr>
<tr>
<td><strong>EXPENSES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2.1 Salaries and related costs</td>
<td>199'066</td>
<td>214'894</td>
<td>214'894</td>
<td>0</td>
</tr>
<tr>
<td>2.2 Outsourced Services</td>
<td>9'014</td>
<td>9'184</td>
<td>10'837</td>
<td>1'653</td>
</tr>
<tr>
<td>2.3 Travel, projects, meetings/representation</td>
<td>39'479</td>
<td>233'500</td>
<td>116'665</td>
<td>-116'835</td>
</tr>
<tr>
<td>2.4 Communication &amp; marketing</td>
<td>30'919</td>
<td>34'000</td>
<td>21'921</td>
<td>-12'079</td>
</tr>
<tr>
<td>2.5 Office accommodation</td>
<td>10'677</td>
<td>11'006</td>
<td>10'718</td>
<td>-288</td>
</tr>
<tr>
<td>2.6 Office Costs &amp; reserve</td>
<td>69'774</td>
<td>27'276</td>
<td>64'605</td>
<td>37'329</td>
</tr>
<tr>
<td>2.7 Other Charges</td>
<td>545</td>
<td>1500</td>
<td>1500</td>
<td>0</td>
</tr>
<tr>
<td>Total Expenses</td>
<td>359'474</td>
<td>531'360</td>
<td>441'140</td>
<td>-90'220</td>
</tr>
<tr>
<td><strong>Net Ordinary Income</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>12'409</td>
<td>11'440</td>
<td>12'012</td>
<td>199'572</td>
</tr>
<tr>
<td><strong>Profit for the Year</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>12'409</td>
<td>11'440</td>
<td>12'012</td>
<td>199'572</td>
</tr>
</tbody>
</table>
Balance Sheet 30 Sept 2014

**ASSETS**

Current Assets
- Accounts Receivable: 51'150
- Prepaid expenses: 835
- Cash at bank: 401'009

Total Assets: 452'994

**LIABILITIES AND RESERVES**

Capital and Reserves
- Reserves: 60'000
- Profit brought forward: 12'411
- Profit for the Year: 256'928

Total Reserves: 329'339

Liabilities
- Accrued expenses: 4'536
- Restricted funds: 119'119

Total Liabilities: 123'655

Total Liabilities and Reserves: 452'994

---

**Bank Movements**

<table>
<thead>
<tr>
<th>Currency</th>
<th>31 August</th>
<th>Receipts</th>
<th>Transfers</th>
<th>Payments</th>
<th>Ex Diff</th>
<th>30 Sept</th>
</tr>
</thead>
<tbody>
<tr>
<td>CHF 7602M</td>
<td>42'621</td>
<td>-</td>
<td>2'905</td>
<td>26'042</td>
<td>-</td>
<td>19'485</td>
</tr>
<tr>
<td>Euro 7640 K</td>
<td>58'966</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>58'966</td>
</tr>
<tr>
<td>Euro 7660C</td>
<td>190'883</td>
<td>132'128</td>
<td>-</td>
<td>452</td>
<td>-</td>
<td>322'558</td>
</tr>
</tbody>
</table>

Total Cash at bank and in hand: 401'009
## Ordinary Income/Expense

### Income

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>1. INCOME</td>
<td>542'800</td>
<td>652'152</td>
<td>457'300</td>
<td>-194'852</td>
</tr>
<tr>
<td>Deferred income from 2014</td>
<td></td>
<td></td>
<td>199'000</td>
<td></td>
</tr>
<tr>
<td><strong>Total Income</strong></td>
<td>542'800</td>
<td>652'152</td>
<td>656'300</td>
<td>-194'852</td>
</tr>
</tbody>
</table>

### Expenses

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>2.1 Salaries and related costs</td>
<td>214'894</td>
<td>214'894</td>
<td>258'700</td>
<td>43'806</td>
</tr>
<tr>
<td>2.2 Outsourced Services</td>
<td>9'184</td>
<td>10'837</td>
<td>9'184</td>
<td>-1'653</td>
</tr>
<tr>
<td>2.3 Travel, projects, meetings/representation</td>
<td>233'500</td>
<td>315'665</td>
<td>253'500</td>
<td>-62'165</td>
</tr>
<tr>
<td>2.4 Communication &amp; marketing</td>
<td>34'000</td>
<td>21'921</td>
<td>46'000</td>
<td>24'079</td>
</tr>
<tr>
<td>2.5 Office accommodation</td>
<td>11'006</td>
<td>10'718</td>
<td>11'280</td>
<td>562</td>
</tr>
<tr>
<td>2.6 Office Costs &amp; reserve</td>
<td>27'276</td>
<td>64'605</td>
<td>63'500</td>
<td>-1'105</td>
</tr>
<tr>
<td>2.7 Other Charges</td>
<td>1'500</td>
<td>1'500</td>
<td>1'500</td>
<td>0</td>
</tr>
<tr>
<td><strong>Total Expense</strong></td>
<td>531'360</td>
<td>640'140</td>
<td>643'664</td>
<td>3'524</td>
</tr>
</tbody>
</table>

**Net Ordinary Income**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>11'440</td>
<td>12'012</td>
<td>12'636</td>
<td>624</td>
<td></td>
</tr>
</tbody>
</table>

**Profit for the Year**

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>11'440</td>
<td>12'012</td>
<td>12'636</td>
<td>624</td>
<td></td>
</tr>
</tbody>
</table>
Amended SIOG Constitution (article 8)
Development of interest groups

Article 8 Amendment

The Board of Directors shall be composed of …. any interest group representative(s) recommended by the Board of Directors…the interest group representatives should hold office for 3 years; they can be re-elected once for a further term.”
Article 8: Board of Directors

8.3 The Board of Directors shall be composed of the following members:
- The President, who assumes the role of Chair of the Board of Directors
- The President-Elect, who shall serve for two years preceding his or her term as President;
- The Immediate Past-President, who shall serve for two years subsequent to his or her term as President.
- The Treasurer
- The Chairpersons of the Permanent Committees
- or any interest group representative(s) recommended by the Board of Directors
- The Chairperson of the Corporate Relations Committee who shall serve as an ex-officio member
- The Chief Executive Officer who shall serve as an ex-officio member

8.5 The President, the President-elect and the past-President shall hold office for 2 years. The Treasurer, the Chairpersons of the Permanent Committees and the interest group representatives should hold office for 3 years; they can be re-elected once for a further term. A member of the Board, other than the ex-officio members indicated in 8.3 may not be on the Board for more than 6 consecutive years. After observance of a three (3) year resting period, Board members, who have already served the Board for six years are again eligible for nomination and election to the Board of Directors.
Amended SIOG Constitution (article 8)
Approval

VOTE
Thank You to Exiting Board Members!

Riccardo Audisio

Christopher Steer
Introduction to
Dr. Etienne Brain
SIOG President 2014-2016
New SIOG Governance (2014-2016)

President – Dr Etienne Brain, France
President-elect – Dr Stuart Lichtman, USA
Treasurer – Dr Hans Wildiers, Belgium
Immediate Past President – Dr Arti Hurria, USA

(GA to confirm)
New SIOG Governance (2014-2016)

Membership & National Representatives Committee
Anita O’Donovan (Ireland), Chair
Tania Estapé (Spain), Member
Jee Hyun Kim (Korea), Member
Demitrios Kardamakis (Greece), Member
Vicki Morrison (USA), Member

Publication Committee
Ulrich Wedding (Germany), Chair
Gouri Shankar Bhattacharyya (India), Member
Andrea Luciani (Italy), Member
Ines Mattos (Brazil), Member
Reinhard Stauder (Austria), Member

Science & Education Committee
Supriya Mohile (USA), Chair
Laura Biganzoli (Italy), Member
Philippe Caillet (France), Member
Kwok Leung Cheung (UK), Member
William Dale (USA), Member
Tina Hsu (Canada), Member
Ravindran Kanesvaran (Singapore), Member
Ronald Maggiore (USA), Member
Demetris Papamichael (Cyprus), Member
Tanya Wildes (USA), Member

(GA to confirm)
Presidential Address

Dr Etienne Brain
SIOG President (2014-2016)
SIOG 2014-2016
Etienne GC Brain, MD PhD
Medical Oncology
Hôpital René Huguenin / Institut Curie
Saint-Cloud, France

http://www.sioe.org
Strategy

2012-2014

I. Research and science
   — Conference

II. Education
   — Partnership with other societies, Plexus, Ecancer, Medscape

III. Financial stability and sustainability

2014-2016

I. Promotion of scientific knowledge

II. Build the future

III. Expand international outreach and dimension
I. Promotion of scientific knowledge (1)

- Direct continuation of previous presidency
- **Guidelines** development (new & updates)
- Access to and use of geriatric tools
- Research
Age distribution for patients enrolled onto National Cancer Institute (NCI) adult cooperative group phase II and III treatment trials (all diseases) from 2001 to 2011.

Hurria A et al. JCO 2014;32:2587-2594

©2014 by American Society of Clinical Oncology
Under-Representation of Older Adults in Cancer Registration Trials: Known Problem, Little Progress
I. Promotion of scientific knowledge (2)

• **Research**
  – Highlight the gaps with unsolved questions
  – Support initiatives from cooperative groups as a facilitator
  – Disseminate and emphasize the practical use of results from research developed by our members (PACE & PREOP, CRASH, CARG, etc.)
  – Promote new methodology
    • Relevant endpoints (preservation of function, cognition and independence)
    • Move from extrapolation to evidence-based health cares
    • De-escalation issues
    • Harness and take maximum advantage of targeted therapies vs conventional treatment (chemo) in order to limit side effects
    • Pharmaco-economic issues
    • Call for a certain degree of assessment of life expectancy to balance treatment decision

“We need less research, better research, and research done for the right reasons” (Douglas Altman), addressing “what is value in health care?”
II. Build the future (1)

• To breathe new/young life
  – Young SIOG committee
  – Increase emphasis on young participation
  – Mentorship
  – Education
  – Fellowships and grants

• Similar challenges to AYA & paediatrics
  – Grapple with age definition
  – Cross all tumours
  – Have a supportive care focus
II. Build the future (2)

- Increase the community
  - Nursing and allied health committee

- Increase multisciplinarity
  - Surgery, XRT, med onc, biostat, pharmacologist, scientist/biologist, etc.
We live in an era of unprecedented, rapid and inexorable global ageing.
III. Expand international outreach and dimension

- **Yearly regional events** (APAC, LATAM, Middle East) alternating with the annual conference
  - Singapore APAC (2014) → follow-up
  - 2015-2016 → LATAM, Middle East, etc.

- **Workshops in low and middle income countries**

- Make full use of **trans- and cross-cultural skills**
Two worlds confronting one another?

- **Young patient**
  - Social and family obligations (children)
  - Quantity of life +++

- **Elderly patient**
  - QoL+++
  - Independence
  - Staying at home

- **Oncology**
  - Therapies and innovation
  - Toxicity, response, survival
    - RECIST
    - NCI CTC v4.0
    - Survival (DFS, PFS, DDFS, OS)
  - Fast-moving world
  - "Molecular portrait" of tumour & GEP

- **Geriatrics**
  - Symptoms, diagnosis
  - Quality of survival, i.e. amount of life with good QoL
    - Cognition
    - Functional status
    - QoL
    - Nutrition, etc.
  - Requiring time
  - "Global portrait" of patient & CGA

---

versus 
or + ? CGA

---
FEC, AACR, FAC, ASCO, CMF, DXR, PK/PD, CEX, 5FU CDDP, Calvert AUC, ESMO, Chatelut AUC, CTC, population PK, FOLFIRI, FOLFOX 7, CPA, DFS, DDFS, OS, TTP, NCI, CYP P450, JCO, JNCI, HER2, PI3K, mTOR, Phase 0, ECCO, ib and ab...etc.

Charlson, CIRSG, CGA, MNA, GDS, MMS, ADL, IADL, GFI, CMR2, JAGS, G8, CARG, Oncodage, VES-13, TRFs, JGO, NIA, Walter’s score, Lee’s score, CRASH...etc.
All of this will help to breathe life from the Lisbon success towards the Prague dream.
Members in the Spotlight!
National Representative of the year
Ravindran Kanesvaran, Consultant, Division of Medical Oncology, National Cancer Centre, Singapore

Dr Ravindran Kanesvaran is a Consultant in the Department of Medical Oncology of the National Cancer Centre Singapore. He is also an Assistant Professor at Duke-NUS Graduate Medical School and clinical senior lecturer at the Yong Loo Lin School of Medicine, National University of Singapore. He is actively involved in graduate medical education and is a core faculty member of the Medical Oncology Senior Residency Program and the Singhealth Internal Medicine Residency Program. He completed his medical oncology specialty training in the National Cancer Centre Singapore. After completion of that training he followed up with a fellowship in genitourinary oncology (GU) and geriatric oncology in Duke Cancer Institute in North Carolina, USA on a Healthcare Manpower Development Program (HMDP) scholarship awarded by the Ministry of Health Singapore. His research interests include GU oncology and geriatric oncology. He has published in a number of well-known peer reviewed journals including Journal of Clinical Oncology and Urology.

He has also been awarded a number of awards including the American Society of Clinical Oncology (ASCO GU) Merit Award 2009, American Association for Cancer Research (AACR) scholar-in-training Award 2010 and European Society of Medical Oncology (ESMO) fellowship award 2012. He is currently the President of the Singapore Society of Oncology (SSO) and the Singapore Geriatric Oncology Society. He is the National Representative for Singapore in the International Society of Geriatric Oncology (SIOG).
Birthdays

Carlo de Angelis (CND) (October 21)

Gerald Sokol (USA) (October 21)

Antonella Brunello (IT) (October 22)

Daniel Rushing (USA) (October 22)

Margot Gosney (UK) (October 24)

Lindsay Stansfield (USA) (October 24)
Thank you